Profile
Michael Vasconcelles is the Head of Research and Development at Day One Biopharmaceuticals, Inc. (DAWN), a clinical-stage biopharma focused on targeted therapies for genetically defined cancers, including pediatric patients. In the most recent SEC filing dated January 30, 2026 (CIK 0001734755), he is listed among Day One's leadership with no reported purchases or sales of the company's securities. He leads the company's research and development strategy and programs, including DAY101.
| Role | Insider |
|---|
| Notability | 40/100 |
|---|
Board memberships
- Day One Biopharmaceuticals, Inc.
Frequently Asked Questions
Who is VASCONCELLES MICHAEL?
Michael Vasconcelles is the Head of Research and Development at Day One Biopharmaceuticals, Inc. (DAWN), a clinical-stage biopharma focused on targeted therapies for genetically defined cancers, including pediatric patients. In the most recent SEC filing dated January 30, 2026 (CIK 0001734755), he is listed among Day One's leadership with no reported purchases or sales of the c…
How many SEC Form 4 filings has VASCONCELLES MICHAEL submitted recently?
2 primary Form 4 filings in the last 90 days, covering 2 companies.
Has VASCONCELLES MICHAEL been buying or selling stock?
Recorded transactions: 0 open-market purchases () and 1 open-market sales ($32K) across all tracked filings.
Where can I see all of VASCONCELLES MICHAEL's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.